PCN72 COMPARATIVE COST ANALYSIS OF SUBCUTANEOUS TRASTUZUMAB ORIGINATOR (HERCEPTIN®) VS INTRAVENOUS TRASTUZUMAB BIOSIMILAR (KANJINTI) FROM A HOSPITAL PERSPECTIVE IN ITALY
Abstract
Authors
A. D'Arpino M. Savoia L. Cirillo N. Despiégel B. Haffemayer A. Giannopoulou I. Gaikwad